Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

(OGXI)

(OGXI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

19820 NORTH CREEK PARKWAY BOTHELL WA 98011 USA

www.oncogenex.com P: 425-686-1500

Description:

Oncogenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011 or custirsen the lead candidate currently completing three Phase 3 clinical studies in prostate and lung cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 2 clinical trials in bladder, lung, pancreas and prostate cancers; and OGX-225 is currently in pre-clinical development.

Key Statistics

Overview:

Market Capitalization, $K 12,040
Shares Outstanding, K 30,100
Annual Sales, $ 5,060 K
Annual Net Income, $ -20,130 K
60-Month Beta 2.02
% of Insider Shareholders 3.30%
% of Institutional Shareholders 13.92%

Growth:

1-Year Return -3.15%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth -8.00%
5-Year Earnings Growth -61.27%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 08/03/17
Earnings Per Share ttm -0.46
EPS Growth vs. Prev Qtr 9.09%
EPS Growth vs. Prev Year 44.44%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

OGXI Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -86.47%
Return-on-Assets % -63.70%
Profit Margin % -397.83%
Debt/Equity 0.00
Price/Sales 2.47
Price/Cash Flow N/A
Price/Book 0.92
Book Value/Share 0.00
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar